Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
54
DOX Quote, Financials, Valuation and Earnings
Last price:
$89.27
Seasonality move
:
-3.24%
Day range:
$88.79 - $89.75
52-week range:
$78.61 - $95.41
Dividend yield:
2.25%
P/E ratio:
18.80x
P/S ratio:
2.10x
P/B ratio:
2.87x
Volume:
453.3K
Avg. volume:
722K
1-year change:
6.47%
Market cap:
$9.9B
Revenue:
$5B
EPS (TTM):
$4.75
Analysts' Opinion
-
Consensus RatingAmdocs has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $102.17, Amdocs has an estimated upside of 14.4% from its current price of $89.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $91.56 representing 100% downside risk from its current price of $89.31.
Fair Value
-
According to the consensus of 6 analysts, Amdocs has 14.4% upside to fair value with a price target of $102.17 per share.
DOX vs. S&P 500
-
Over the past 5 trading days, Amdocs has underperformed the S&P 500 by -0.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Amdocs does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amdocs revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Amdocs reported revenues of $1.1B.
Earnings Growth
-
Amdocs has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Amdocs reported earnings per share of $1.45.
Enterprise value:
10.3B
EV / Invested capital:
--
Price / LTM sales:
2.10x
EV / EBIT:
15.86x
EV / Revenue:
2.17x
PEG ratio (5yr expected):
2.79x
EV / Free cash flow:
17.11x
Price / Operating cash flow:
16.59x
Enterprise value / EBITDA:
12.30x
Gross Profit (TTM):
$1.7B
Return On Assets:
8.54%
Net Income Margin (TTM):
11.39%
Return On Equity:
15.34%
Return On Invested Capital:
12.96%
Operating Margin:
17.53%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $4.7B | $5B | $4.8B | $1.2B | $1.1B | |
| Gross Profit | $1.7B | $1.7B | $1.7B | $443.9M | $430.2M | |
| Operating Income | $697.9M | $741.2M | $789.8M | $188.9M | $197.7M | |
| EBITDA | $900.4M | $833.1M | $837.3M | $207.7M | $244.1M | |
| Diluted EPS | $4.39 | $4.45 | $4.75 | $1.01 | $1.45 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.3B | $2.1B | $2.1B | $1.8B | $1.6B | |
| Total Assets | $6.6B | $6.6B | $6.5B | $6.4B | $6.2B | |
| Current Liabilities | $1.3B | $1.4B | $1.3B | $1.4B | $1.3B | |
| Total Liabilities | $3B | $3B | $2.8B | $2.8B | $2.7B | |
| Total Equity | $3.6B | $3.6B | $3.6B | $3.6B | $3.5B | |
| Total Debt | $744.3M | $644.8M | $645.4M | $646M | $646.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $761.4M | $760M | $687.4M | $132.7M | $172.5M | |
| Cash From Investing | -$180.5M | -$292.2M | $10.6M | -$17.2M | $43.9M | |
| Cash From Financing | -$550.6M | -$748.2M | -$793.5M | -$155.5M | -$182.8M | |
| Free Cash Flow | $569.9M | $641.1M | $601.9M | $113.1M | $156.5M | |
DOX
Sector
Market Cap
$9.9B
$83.5M
Price % of 52-Week High
93.61%
64.2%
Dividend Yield
2.25%
0%
Shareholder Yield
7.74%
0.68%
1-Year Price Total Return
6.47%
-12.88%
Beta (5-Year)
0.515
0.814
Dividend yield:
2.25%
Annualized payout:
$1.87
Payout ratio:
40.3%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$89.62
200-day SMA
Buy
Level
$88.23
Bollinger Bands (100)
Sell
Level
86.37 - 92.39
Chaikin Money Flow
Sell
Level
-2.3M
20-day SMA
Sell
Level
$90.89
Relative Strength Index (RSI14)
Sell
Level
43.57
ADX Line
Sell
Level
31.3
Williams %R
Neutral
Level
-74.1472
50-day SMA
Sell
Level
$91.42
MACD (12, 26)
Buy
Level
24.71
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-795.7K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.7129)
Buy
CA Score
(Annual)
Level (0.4881)
Buy
Beneish M-Score
(Annual)
Level (-2.7277)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-1.0118)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.
Stock Forecast FAQ
In the current month, DOX has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DOX average analyst price target in the past 3 months is $102.17.
-
Where Will Amdocs Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amdocs share price will rise to $102.17 per share over the next 12 months.
-
What Do Analysts Say About Amdocs?
Analysts are divided on their view about Amdocs share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amdocs is a Sell and believe this share price will drop from its current level to $91.56.
-
What Is Amdocs's Price Target?
The price target for Amdocs over the next 1-year time period is forecast to be $102.17 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DOX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amdocs is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DOX?
You can purchase shares of Amdocs via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amdocs shares.
-
What Is The Amdocs Share Price Today?
Amdocs was last trading at $89.27 per share. This represents the most recent stock quote for Amdocs. Yesterday, Amdocs closed at $89.31 per share.
-
How To Buy Amdocs Stock Online?
In order to purchase Amdocs stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 13.2% over the past day.
